Department of Anatomy & Neurobiology, Reeve-Irvine Research Center, Sue & Bill Gross Stem Cell Research Center, University of California at Irvine, 1101 Gross Hall, 845 Health Science Rd., Irvine, CA 92697-4265, USA.
Prog Retin Eye Res. 2012 Nov;31(6):661-87. doi: 10.1016/j.preteyeres.2012.06.003. Epub 2012 Jul 5.
Retinal diseases such as age-related macular degeneration (ARMD) and retinitis pigmentosa (RP) affect millions of people. Replacing lost cells with new cells that connect with the still functional part of the host retina might repair a degenerating retina and restore eyesight to an unknown extent. A unique model, subretinal transplantation of freshly dissected sheets of fetal-derived retinal progenitor cells, combined with its retinal pigment epithelium (RPE), has demonstrated successful results in both animals and humans. Most other approaches are restricted to rescue endogenous retinal cells of the recipient in earlier disease stages by a 'nursing' role of the implanted cells and are not aimed at neural retinal cell replacement. Sheet transplants restore lost visual responses in several retinal degeneration models in the superior colliculus (SC) corresponding to the location of the transplant in the retina. They do not simply preserve visual performance - they increase visual responsiveness to light. Restoration of visual responses in the SC can be directly traced to neural cells in the transplant, demonstrating that synaptic connections between transplant and host contribute to the visual improvement. Transplant processes invade the inner plexiform layer of the host retina and form synapses with presumable host cells. In a Phase II trial of RP and ARMD patients, transplants of retina together with its RPE improved visual acuity. In summary, retinal progenitor sheet transplantation provides an excellent model to answer questions about how to repair and restore function of a degenerating retina. Supply of fetal donor tissue will always be limited but the model can set a standard and provide an informative base for optimal cell replacement therapies such as embryonic stem cell (ESC)-derived therapy.
视网膜疾病,如年龄相关性黄斑变性(AMD)和色素性视网膜炎(RP),影响着数以百万计的人。用与宿主视网膜仍具有功能部分相连接的新细胞替代丢失的细胞,可能修复退化的视网膜,并在未知程度上恢复视力。一种独特的模型,即胎儿来源的视网膜祖细胞的视网膜下移植,结合其视网膜色素上皮(RPE),在动物和人类中都显示出了成功的结果。大多数其他方法仅限于通过植入细胞的“护理”作用,在疾病早期阶段拯救受体的内源性视网膜细胞,而不是针对神经视网膜细胞的替代。薄片移植可恢复几个视网膜变性模型中高级视丘(SC)中丢失的视觉反应,其对应于移植在视网膜中的位置。它们不仅简单地保持视觉性能——它们增加了对光的视觉反应。SC 中视觉反应的恢复可以直接追溯到移植中的神经细胞,表明移植和宿主之间的突触连接有助于视觉改善。移植过程侵入宿主视网膜的内丛状层,并与可能的宿主细胞形成突触。在 RP 和 AMD 患者的 II 期试验中,视网膜及其 RPE 的移植提高了视力。总之,视网膜祖细胞薄片移植为回答如何修复和恢复退化视网膜功能的问题提供了一个极好的模型。胎儿供体组织的供应将始终受到限制,但该模型可以为胚胎干细胞(ESC)衍生疗法等最佳细胞替代疗法设定标准并提供信息基础。